Amita Patnaik
About
Amita Patnaik is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Amita Patnaik has authored 365 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Oncology, 141 papers in Molecular Biology and 100 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amita Patnaik's work include Cancer Immunotherapy and Biomarkers (83 papers), Lung Cancer Treatments and Mutations (54 papers) and Colorectal Cancer Treatments and Studies (46 papers). Amita Patnaik is often cited by papers focused on Cancer Immunotherapy and Biomarkers (83 papers), Lung Cancer Treatments and Mutations (54 papers) and Colorectal Cancer Treatments and Studies (46 papers). Amita Patnaik collaborates with scholars based in United States, Canada and France. Amita Patnaik's co-authors include Anthony W. Tolcher, Eric K. Rowinsky, Kyriakos P. Papadopoulos, Muralidhar Beeram, Leena Gandhi, Matthew A. Gubens, Drew Rasco, Johann S. de Bono, Shirish M. Gadgeel and James Stevenson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Amita Patnaik
353 papers receiving 14.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Amita Patnaik United States | 62 | 8.4k | 6.2k | 4.5k | 2.7k | 2.1k | 365 | 14.4k | ||
| Anthony W. Tolcher United States | 62 | 7.2k 0.9× | 8.8k 1.4× | 3.7k 0.8× | 2.0k 0.7× | 2.3k 1.1× | 438 | 16.5k | ||
| Jeffrey R. Infante United States | 63 | 9.0k 1.1× | 6.9k 1.1× | 3.5k 0.8× | 2.2k 0.8× | 2.5k 1.2× | 343 | 14.8k | ||
| Johanna C. Bendell United States | 63 | 9.4k 1.1× | 5.4k 0.9× | 4.3k 1.0× | 1.9k 0.7× | 2.1k 1.0× | 535 | 14.8k | ||
| Igor Puzanov United States | 59 | 10.2k 1.2× | 6.8k 1.1× | 3.2k 0.7× | 3.9k 1.4× | 1.8k 0.9× | 302 | 15.5k | ||
| Frank G. Haluska United States | 51 | 10.9k 1.3× | 7.9k 1.3× | 8.0k 1.8× | 2.8k 1.0× | 3.0k 1.5× | 138 | 18.7k | ||
| Bart Neyns Belgium | 53 | 9.8k 1.2× | 4.2k 0.7× | 2.6k 0.6× | 4.4k 1.6× | 1.6k 0.8× | 316 | 13.9k | ||
| Kim Margolin United States | 63 | 11.0k 1.3× | 6.5k 1.1× | 5.6k 1.3× | 5.5k 2.0× | 2.5k 1.2× | 312 | 17.9k | ||
| Harriet M. Kluger United States | 59 | 7.7k 0.9× | 5.1k 0.8× | 3.1k 0.7× | 3.5k 1.3× | 1.3k 0.7× | 319 | 12.4k | ||
| Naiyer A. Rizvi United States | 61 | 11.0k 1.3× | 3.5k 0.6× | 7.7k 1.7× | 3.0k 1.1× | 2.2k 1.1× | 275 | 15.0k | ||
| Steven O’Day United States | 52 | 9.5k 1.1× | 4.7k 0.8× | 2.4k 0.5× | 4.6k 1.7× | 1.4k 0.7× | 198 | 12.9k |
Countries citing papers authored by Amita Patnaik
Since
Specialization
Citations
This map shows the geographic impact of Amita Patnaik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amita Patnaik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amita Patnaik more than expected).
Fields of papers citing papers by Amita Patnaik
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Amita Patnaik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amita Patnaik. The network helps show where Amita Patnaik may publish in the future.
Co-authorship network of co-authors of Amita Patnaik
This figure shows the co-authorship network connecting the top 25 collaborators of Amita Patnaik. A scholar is included among the top collaborators of Amita Patnaik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amita Patnaik. Amita Patnaik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Falchook, Gerald S., Amita Patnaik, Debra L. Richardson, et al.. (2024). A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clinical Therapeutics. 46(3). 228–238.
2.
Davar, Diwakar, Ludimila Cavalcante, Nehal J. Lakhani, et al.. (2024). Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for ImmunoTherapy of Cancer. 12(8). e009474–e009474.
3.
Patnaik, Amita, Meredith Pelster, David S. Hong, et al.. (2024). A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.. Journal of Clinical Oncology. 42(16_suppl). TPS3172–TPS3172.
4.
Hong, David S., Michael A. Postow, Bartosz Chmielowski, et al.. (2023). Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical Cancer Research. 29(12). 2210–2219.
5.
Patnaik, Amita, Minal Barve, Manali Bhave, et al.. (2023). Abstract P4-01-35: A Phase 1 Study of the Oral CDK7 Inhibitor XL102 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (QUARTZ-101): Initial Results From the Dose-Escalation Stage. Cancer Research. 83(5_Supplement). P4–1.
6.
Harding, James J., Víctor Moreno, Yung‐Jue Bang, et al.. (2021). Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clinical Cancer Research. 27(8). 2168–2178.
7.
Patnaik, Amita, Timothy A. Yap, Hyun Cheol Chung, et al.. (2020). Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. Clinical Cancer Research. 27(5). 1267–1277.
8.
Tolcher, Anthony W., Mario Sznol, Siwen Hu‐Lieskovan, et al.. (2017). Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 23(18). 5349–5357.
9.
Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674.
10.
Patnaik, Amita, Glen J. Weiss, John E. Leonard, et al.. (2015). Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 827–836.
11.
Papadopoulos, Kyriakos P., Robin Kate Kelley, Anthony W. Tolcher, et al.. (2015). A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(6). 1348–1355.
12.
Dienstmann, Rodrigo, Amita Patnaik, Rocio García‐Carbonero, et al.. (2015). Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery. 5(6). 598–609.
13.
Papadopoulos, Kyriakos P., Josep Tabernero, Ben Markman, et al.. (2014). Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(9). 2445–2456.
14.
Yan, Xin, Jessica Li, Jenny Wu, et al.. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(21). 6040–6048.
15.
Shimizu, Toshio, Anthony W. Tolcher, Kyriakos P. Papadopoulos, et al.. (2012). The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer. Clinical Cancer Research. 18(8). 2316–2325.
16.
Tolcher, Anthony W., Christopher J. Sweeney, K. Papadopoulos, et al.. (2011). Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin. Clinical Cancer Research. 17(2). 363–371.
17.
Mita, Monica, Alain C. Mita, Quincy S. Chu, et al.. (2008). Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies. Journal of Clinical Oncology. 26(3). 361–367.
18.
Tolcher, Anthony W., Amita Patnaik, Kyriakos P. Papadopoulos, et al.. (2007). Safety and pharmacokinetics of oblimersen administered as a weekly 2-hour intravenous infusion. Molecular Cancer Therapeutics. 6.
19.
Ratain, Mark J., Tim Eisen, Walter M. Stadler, et al.. (2006). Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(16). 2505–2512.
20.
Tolcher, Anthony W., Desirée Hao, Johann S. de Bono, et al.. (2006). Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer. Journal of Clinical Oncology. 24(13). 2052–2058.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Anthony W. Tolcher Breakdown of academic impact, for papers by Jeffrey R. Infante Breakdown of academic impact, for papers by Johanna C. Bendell Breakdown of academic impact, for papers by Igor Puzanov Breakdown of academic impact, for papers by Frank G. Haluska Breakdown of academic impact, for papers by Bart Neyns Breakdown of academic impact, for papers by Kim Margolin Breakdown of academic impact, for papers by Harriet M. Kluger Breakdown of academic impact, for papers by Naiyer A. Rizvi Breakdown of academic impact, for papers by Steven O’Day